Should more patients with ischemic stroke be eligible for tPA treatment?
Claire Braybrook
This article has no abstract so we have provided the first paragraph of the full text.
Many patients with ischemic stroke are not treated with intravenous tissue plasminogen activator (tPA) if their symptoms are deemed mild. Such patients are classified as being 'too good to treat' (TGT)—that is, the benefit they are likely to receive from the therapy is perceived to not outweigh the increased risk of hemorrhage with which it is associated. Questions have been raised regarding this strategy, however, after 32% of TGT patients in one study died or could not be discharged from hospital.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
